Prosecution Insights
Last updated: October 04, 2026
Application No. 17/535,297

GENE FOR PARTHENOGENESIS

Final Rejection §112
Filed
Nov 24, 2021
Priority
May 29, 2019 — EU 19177252.4 +3 more
Examiner
MEADOWS, CHRISTINA L
Art Unit
1663
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Keygene N V
OA Round
7 (Final)
76%
Grant Probability
Favorable
8-9
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
51 granted / 67 resolved
+16.1% vs TC avg
Strong +23% interview lift
Without
With
+23.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
33 currently pending
Career history
105
Total Applications
across all art units

Statute-Specific Performance

§101
7.0%
-33.0% vs TC avg
§103
28.4%
-11.6% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
45.4%
+5.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 67 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims The amendments received on 05/19/2026 have been entered. Claims 14-21, 23, 26, 28, 32-33, and 35 are pending. Claim 14 has been amended. Claims 16-20 remain withdrawn from active consideration. Claims 14-15, 21, 23, 26, 28, 32-33, and 35 are examined in this Office Action. Objections and Rejections that are Withdrawn The 35 USC 112(a) Written Description rejection to claims 14-15, 21, 23, 26, 28, and 32-33 for the recitation of “zinc finger C2H2-type domain” has been withdrawn in light of Applicant’s amendment to the claims. The text of those sections of Title 35, U.S. Code, not included in this action, can be found in a prior Office action. Claim Rejections - 35 USC § 112 Written Description Claims 14-15, 21, 23-24, 26, 28, 32-33, and 35 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a modified rejection necessitated by claim amendment. All dependent claims are included in these rejections unless they include a limitation that overcomes the deficiencies of the parent claim. The claims are broadly drawn to a method for producing a parthenogenetic plant, comprising: (a) introducing in one or more plant cells a parthenogenetic allele for expression of a parthenogenesis (PAR) protein comprising a sequence according to SEQ ID NO: 1 or a homologous or orthologous sequence thereof, wherein the parthenogenetic allele comprises an egg cell specific promoter operably linked to a sequence encoding the PAR protein, wherein the PAR protein is functional in parthenogenesis, wherein the PAR protein comprises a zinc finger K2-2-like domain having SEQ ID NO: 37 and an EAR motif having SEQ ID NO: 58 or 59, resulting in expression of the PAR protein in an egg cell, and wherein the one or more plant cells are angiosperms from an Asteraceae (Compositae) family; (b) selecting a plant cell comprising the parthenogenetic allele ; and (c) regenerating an angiosperm plant from said plant cell. Applicant describes: The identification of PAR proteins in several plants (Specification, Table 1, page 42). The presence of a MITE or MITE-like sequence being indicative for the parthenogenic phenotype (Specification, page 48, lines 4-6). A promoter sequence of a PAR gene may be replaced by the promoter of the Taraxacum Par allele. Upon introduction, plants will obtain the parthenogenesis trait (Specification, , page 48, lines 9-13). Applicant has not described: Any reduction to practice for causing parthenogenesis in an angiosperm from an Asteraceae (Compositae) family other than lettuce (Specification, Example 2, pages 46-47). Any reduction to practice for causing parthenogenesis by using a homologous or orthologous sequence of SEQ ID NO: 1. Any reduction to practice for causing parthenogenesis by using a variant having 90% sequence identity with SEQ ID NO: 5. Applicant has claimed an extremely large genus of angiosperm plants from an Asteraceae (Compositae) family. Asteraceae is a large family of flowering plants that consists of over 32,000 known species in over 1,900 genera within the order Asterales. The number of species in Asteraceae is rivaled only by the Orchidaceae, and which is the larger family is unclear as the quantity of extant species in each family is unknown. The Asteraceae were first described in the year 1740 and given the original name Compositae. The family is commonly known as the aster, daisy, composite, or sunflower family (iNaturalist, https://www.inaturalist.org/taxa/47604-Asteraceae, accessed 02/13/2026) . Most species of Asteraceae are herbaceous plants, and may be annual, biennial, or perennial, but there are also shrubs, vines, and trees. The family has a widespread distribution, from subpolar to tropical regions, in a wide variety of habitats. Most occur in hot desert and cold or hot semi-desert climates, and they are found on every continent but Antarctica (iNaturalist, https://www.inaturalist.org/ taxa/47604-Asteraceae, accessed 02/13/2026). It is noted that at the time of filing the Applicant had only reduced to practice the transformation of lettuce. Hypothetical host plants do not provide evidence of a reduction to practice of a representative number of species across the breadth of the claimed genus of all angiosperms from an Asteraceae (Compositae) family. A Written Description rejection is based on what the Applicant was in possession of at the time of filing. Additionally, with this in mind, the Applicant and author Underwood (Underwood et al., Nature Genetics, 2022, Vol. 54, pp. 84-93, see List of References Cited by Examiner dated 11/20/2023) describes introducing the Taraxacum PAR promoter (SEQ ID NO: 2) in the PAR homolog of Lactuca sativa (lettuce) to induce parthenogenesis. The PAR::Lssex construct led to seed production and tetraploid offspring in four independent transformants, demonstrating that the Taraxacum PAR promoter can invoke a lettuce gene to induce parthenogenesis (Results section, pp. 88-90). Taraxacum officinale (dandelion), Lactuca sativa (lettuce), and Hieracium piloselloides (hawkweed) are related species, all belonging to the Family Asteraceae (Supplementary Figure 15, page 18). Yet, according to the Peer Review Information (page 26), Underwood describes that they were unable to transform the Hieracium LoP (Loss of Parthenogenesis) genotype, noting that the lettuce homolog is phylogenetically more distant from dandelion than hawkweed. This shows the unpredictability of the claimed invention even in related species of angiosperms from the Asteraceae (Compositae) family. Thus, Applicant did not actually possess the successful transformation of Hieracium at the time of filing, but was in possession of the successful transformation of lettuce. The instant specification does not describe any homologous or orthologous sequence of the amino acid sequence of SEQ ID NO: 1 that is capable of inducing parthenogenesis in a plant. The instant specification (Example 2, page 47, lines 21-28) demonstrates that the Par allele gene of Taraxacum officinale is by itself sufficient to induce embryo formation in lettuce. The instant specification further states that “similar results are expected when the lettuce homolog (SEQ ID NO: 22) is used for plant transformation in the same way, e.g., transforming said lettuce plant with a vector comprising a T-DNA region comprising a EC1.1 promoter of Arabidopsis thaliana driving expression of a sequence encoding the lettuce homologue (SEQ ID NO: 22) with a 35S terminator and a neomycin phosphotransferase gene (nptll) for selection”. However, Ali (Ali et al., 2019, Frontiers in Plant Science, Vol. 10, pp. 1-14, see List of References Cited by Examiner dated 09/11/2024) describes that the identification and construction of in-silico promoter models has enabled more accurate prediction of gene expression, whereas the in-silico predictions of gene regulatory events must be validated experimentally (Ali, page 3, left column). The use of SEQ ID NO: 22 to induce embryo formation in lettuce was not reduced to practice in lettuce or in any other plant. A BLAST® of instant sequence SEQ ID NO: 1 shows several hypothetical and unnamed proteins that would not be recognized in the art as homologous or orthologous sequences of the PAR protein of instant sequence SEQ ID NO: 1 (see BLAST® results below). It is also noted that only one protein, hypothetical protein LXL04_019396 [from Taraxacum kok-saghyz], falls within the at least 90% sequence identity with SEQ ID NO: 1 as required by claim 33. PNG media_image1.png 257 752 media_image1.png Greyscale The instant specification does not describe any other sequence having at least 90% sequence identity with SEQ ID NO: 5, or a variant thereof, that is capable of causing parthenogenesis. A BLAST® of instant sequence SEQ ID NO: 5 discloses two short (36 and 39 nucleotides, respectively) sequences that would not be recognized in the art as variants thereof of instant sequence SEQ ID NO: 5 (see BLAST® results below). PNG media_image2.png 123 1210 media_image2.png Greyscale Given that there have not been an adequate number of species reduced to practice to be representative of the broad genus of angiosperms from an Asteraceae (Compositae) family, homologous or orthologous sequences of the amino acid sequence of SEQ ID NO: 1 that are capable of causing parthenogenesis, or sequences having at least 90% sequence identity with SEQ ID NO: 5 or a variant thereof that are capable of causing parthenogenesis, there is not an adequate description to support the breadth of the claim. Response to Arguments Applicant’s arguments filed 05/19/2026 have been fully considered but they are not persuasive. Applicant argues that by showing the effect of Par in Taraxacum officinale and Lactuca sativa, two distant species, the disclosure of the species is sufficient to convey that the inventor possessed the subject matter of the genus, and the genus is supported by an adequate written description (Remarks, page 5). Applicant further argues that “Applicant had not ‘only reduced to practice the transformation of lettuce’” (Remarks, pages 5 and 6). The Examiner respectfully disagrees. The instant Specification discloses dandelions (Taraxacum sp.), and hawkweeds (Hieracium sp.) as gametophytic apomicts (the embryo arises from an unreduced, unfertilized egg cell by parthenogenesis) (page 1, lines 28-35). Applicant identified the PAR gene in Taraxacum officinale by showing that mutations in the Par gene in Taraxacum officinale resulted in the loss of parthenogenesis. Applicant reduced to practice the expression of the Par gene of Taraxacum officinale in egg cells of Lactuca sativa resulting in the induction of parthenogenesis. Applicant did not reduce to practice any variant of the Taraxacum officinale Par gene having less than 100% sequence identity to instant sequence SEQ ID NO: 5 resulting in parthenogenesis in any other angiosperm from the Asteraceae (Compositae) family other than Lactuca sativa (lettuce). Nor did Applicant reduce to practice any homolog or ortholog of the Taraxacum officinale Par gene resulting in parthenogenesis in any angiosperm from the Asteraceae (Compositae) family. Additionally, as stated in the Written Description rejection above, Taraxacum officinale (dandelion), Lactuca sativa (lettuce), and Hieracium piloselloides (hawkweed) are related species, all belonging to the Family Asteraceae; yet, Applicant describes being unable to transform the natural gametophytic apomict Hieracium, noting that the lettuce homolog is phylogenetically more distant from dandelion than hawkweed. Therefore, the transformation of Lactuca sativa with the Par gene from Taraxacum officinale is not representative of all homologs and orthologs of the Par gene from Taraxacum officinale, nor is it representative of all angiosperms of the entire Asteraceae (Compositae) family. Lack of Scope of Enablement Claims 14-15, 21, 23-24, 26, 28, 32-33, and 35 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for causing parthenogenesis by transferring the whole PAR gene (SEQ ID NO: 5) via cross-pollination of Taraxacum (Example 4, Specification, pages 48-49), does not reasonably provide enablement for a homolog or ortholog of SEQ ID NO: 1 (PAR allele protein) inducing parthenogenesis in all angiosperms from the Asteraceae (Compositae) family. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. This is a modified rejection necessitated by claim amendment. All dependent claims are included in this rejection unless they include a limitation that overcomes the deficiencies of the parent claim. The claims are broadly drawn to a method for producing a parthenogenetic plant, comprising: (a) introducing in one or more plant cells a parthenogenetic allele for expression of a parthenogenesis (PAR) protein comprising a sequence according to SEQ ID NO: 1 or a homologous or orthologous sequence thereof, wherein the parthenogenetic allele comprises an egg cell specific promoter operably linked to a sequence encoding the PAR protein, wherein the PAR protein is functional in parthenogenesis, wherein the PAR protein comprises a zinc finger K2-2-like domain having SEQ ID NO: 37 and an EAR motif having SEQ ID NO: 58 or 59, resulting in expression of the PAR protein in an egg cell, and wherein the one or more plant cells are angiosperms from an Asteraceae (Compositae) family; (b) selecting a plant cell comprising the parthenogenetic allele ; and (c) regenerating an angiosperm plant from said plant cell. The full scope of the claimed invention is not enabled because it is unpredictable whether and how any homologous or orthologous sequence of the amino acid sequence of SEQ ID NO: 1 would be capable of inducing parthenogenesis in all angiosperm plants from the Asteraceae (Compositae) family. As stated in the Written Description rejection above, Underwood (2022) describes introducing the Taraxacum PAR promoter (SEQ ID NO: 2) in the PAR homolog of Lactuca sativa (lettuce) to induce parthenogenesis. Taraxacum officinale (dandelion), Lactuca sativa (lettuce), and Hieracium piloselloides (hawkweed) are related species, all belonging to the Family Asteraceae (Supplementary Figure 15, page 18), yet Underwood was unable to transform the Hieracium LoP (Loss of Parthenogenesis) genotype. This shows the unpredictability of the claimed invention even in related species. At the time of application, it was unpredictable whether any homologous or orthologous sequence of the amino acid sequence of SEQ ID NO: 1 is capable of inducing parthenogenesis in any angiosperm plant from an Asteraceae (Compositae) family other than lettuce. Therefore, it would require undue experimentation for one of skill in the art to use trial and error to determine which purported PAR proteins would be capable of conferring parthenogenesis. Additionally, the specification does not describe any sequence having less than 100% sequence identity with SEQ ID NO: 5, or a variant thereof, that is capable of causing parthenogenesis. Example 4 of the instant specification teaches the full-length sequence SEQ ID NO: 5 causing parthenogenesis in Taraxicum brevicomiculatum (page 48-49). It is unpredictable whether and how a sequence having less than 100% identity to SEQ ID NO: 5, or a variant thereof, would function to cause parthenogenesis in a plant, since induction of parthenogenesis relies on the presence of specific nucleotides and nucleotide sequence motifs in a particular arrangement to mediate parthenogenetic function. For example, Underwood (Underwood et al., 2022, Nature Genetics, Vol. 54, pp.84-93) describes a conserved MITE 1,335-bp insertion in the upstream promoter region present in all apomicts and absent in all sexuals (page 88, left column, third paragraph). In the instant case, the specification does not provide sufficient guidance with respect to how to alter the nucleotide sequence of SEQ ID NO: 5 in a manner that does not disrupt its ability to induce parthenogenesis. Absent such guidance one skilled in the art would have to make each of the polynucleotides having at least 90% identity to SEQ ID NO: 5, and then test the ability of each polynucleotide variant to induce parthenogenesis, in order to determine whether and how a polynucleotide variant can be used to induce parthenogenesis. Such a trial-and-error approach to practicing the claimed invention would constitute undue experimentation. Response to Arguments Applicant’s arguments filed 11/26/2025 have been fully considered but they are not persuasive. Applicant argues that using the teachings of the Specification, the skilled person could easily identify PAR homologs and orthologs as proven by Song and Huang; also, the Applicant could not yet successfully transform the Hieracium LoP genotype, but suggested using a more phylogenetically distant Par homolog (Remarks, pages 7-8). However, it would certainly constitute a burden to identify all Par homologs and orthologs, and then test the ability of each Par homolog or ortholog to induce expression in the egg cell of all angiosperms from the Asteraceae (Compositae) family, thereby resulting in parthenogenesis. Such a trial-and-error approach to practicing the claimed invention would indeed constitute undue experimentation. Summary No claim is allowed. Claims 14-15, 21, 23, 26, 28, 32-33, and 35 are free of the prior art, due to the failure of the prior art to teach or suggest instant sequences SEQ ID NO: 1 or SEQ ID NO: 5 inducing parthenogenesis in any plant. The Examiner believes there might be allowable subject matter, but the claims would need to be drafted in a way to avoid 112 issues. For example, Applicant may want to limit the broad genus of plants to lettuce, limit the broad genus of homologs and orthologs of SEQ ID NO: 1 to only SEQ ID NO: 1, and adopt the 95% sequence identity language (see claim 35). Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINA MEADOWS whose telephone number is (703)756-1430. The examiner can normally be reached Monday - Friday 9:00 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amjad Abraham can be reached on 571-270-7058. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CHRISTINA MEADOWS Examiner Art Unit 1663 /CHRISTINA L MEADOWS/Examiner, Art Unit 1663 /Amjad Abraham/SPE, Art Unit 1663
Read full office action

Prosecution Timeline

Show 13 earlier events
Apr 29, 2025
Final Rejection mailed — §112
Jul 28, 2025
Request for Continued Examination
Jul 29, 2025
Response after Non-Final Action
Aug 28, 2025
Non-Final Rejection mailed — §112
Nov 26, 2025
Response Filed
Feb 19, 2026
Non-Final Rejection mailed — §112
May 19, 2026
Response Filed
Aug 26, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12742173
ANTHOCYANIN BIOSYNTHESIS IN CARROT PLANTS
4y 8m to grant Granted Sep 22, 2026
Patent 12741994
PEPTIDE HAVING PLANT STEM CELL-INDUCING EFFECT AND PLANT PEST RESISTANCE-INDUCING EFFECT
3y 6m to grant Granted Sep 22, 2026
Patent 12714047
SOYBEAN VARIETY 5PCNG46
2y 5m to grant Granted Aug 25, 2026
Patent 12708080
METHOD FOR MAGNETIC TRANSFECTION OF MAIZE POLLEN
3y 2m to grant Granted Aug 18, 2026
Patent 12702104
SOYBEAN VARIETY
2y 6m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

8-9
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+23.2%)
2y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 67 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month